Gastric Neuroendocrine Tumors Drug Pipeline Analysis Report 2024

Studies suggest that gastric neuroendocrine tumors are rare tumors which account for approximately 8% of all neuroendocrine tumors and affect approximately 4 in 100,000 people. The tumor forms in the lining of the gastrointestinal tract and mainly affects people aged 55 to 65. Several new types of treatment are being tested including targeted therapy which uses drugs or other substances to attack specific cancer cells. These studies test new drugs and treatment strategies offering patients access to novel therapies.

Report Coverage

The Gastric Neuroendocrine Tumors Drug Pipeline Report by Expert Market Research gives comprehensive insights into gastric neuroendocrine tumors drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for gastric neuroendocrine tumors. The report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from gastric neuroendocrine tumors.

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to gastric neuroendocrine tumors are covered. 

Gastric Neuroendocrine Tumors Drug Pipeline Outlook

Gastrointestinal neuroendocrine tumor is a rare cancerous tumor in neuroendocrine cells of the gastrointestinal tract. These neuroendocrine cells link the nervous system and endocrine system. The common symptoms include stomach pain, diarrhea, nausea and vomiting, unintentional weight loss, jaundice, and fatigue among others. People having multiple endocrine neoplasias and neurofibromatosis type 1 are more likely to develop gastric neuroendocrine tumors. The diagnostic procedures used for the condition include X-rays, computed tomography scans, magnetic resonance imaging, endoscopic ultrasounds, and positron emission tomography scans among others. 

There are three grades of neuroendocrine tumors including grade 1 (low-grade tumor), in which cells divide at a low rate, grade 2 (intermediate-grade tumor), in which cells divide at an intermediate rate and grade 3 (high-grade tumor), in which cells divide at a fast rate. There are several ways to treat gastric neuroendocrine tumors such as active surveillance, surgery, and medical treatments. Surgery for tumors depends on the location of tumor and includes partial gastrectomy, small intestine resection, and appendectomy among others. Additionally, the drugs used include chemotherapy, targeted therapy, immunotherapy, radiation therapy, and somatostatin analogs. There are several drugs are being tested and in a recent study, Lutathera showed promising results as part of initial therapy for some neuroendocrine tumors including gastric tumors. The subjects who received Lu 177-dotatate plus octreotide lived almost three times as long without their cancer getting a worse stage. Several pharmaceutical companies and research institutes are developing innovative treatments to manage the tumor.

Gastric Neuroendocrine Tumors – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of gastric neuroendocrine tumors drugs based on several segmentations including:

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase.

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products 

By Drug Class

EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:

• Small Molecule
• Monoclonal Antibody
• Peptide
• Polymer

By Route of Administration

EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Gastric Neuroendocrine Tumors – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for gastric neuroendocrine tumors pipeline drugs.

Gastric Neuroendocrine Tumors – Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under gastric neuroendocrine tumors pipeline analysis include small molecule, monoclonal antibody, peptide, and polymer. Several therapeutic agents are under observation for treating gastric neuroendocrine tumors including VEGF monoclonal antibody, bevacizumab, and VEGF tyrosine kinase inhibitors. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for gastric neuroendocrine tumors. 

Gastric Neuroendocrine Tumors Clinical Trials Assessment – Competitive Dynamics

The EMR report for the gastric neuroendocrine tumors drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in gastric neuroendocrine tumors clinical trials:

• Ipsen
• Camurus AB
• TaiRx, Inc.
• Aadi Bioscience, Inc.
• Chimeric Therapeutics
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• RayzeBio, Inc.
• Novartis Pharmaceuticals
• Fusion Pharmaceuticals Inc.
• MedInnovation GmbH
• Trio Medicines Ltd.
• Hoffmann-La Roche
• Vedanta Biosciences, Inc.
• Others 

Gastric Neuroendocrine Tumors – Pipeline Drugs Profile

Drug: Pasireotide

The trial is designed to assess the safety of pasireotide LAR in combination with everolimus in patients with gastroenteropancreatic or neuroendocrine tumors. The trial is sponsored by Novartis Pharmaceuticals and is currently under phase I.

Biological: VE800 and Drug: Nivolumab

The objective of the study is to assess the safety and efficacy of VE800 in combination with nivolumab in patients with selected types of advanced cancer. The trial is sponsored by Vedanta Biosciences, Inc. and is currently under phase I/II.

Drug: Pasireotide

RECORDATI GROUP is developing the drug and is currently under phase IV. The study is being conducted to demonstrate the continuous use of pasireotide in patients who are taking pasireotide treatment in a Novartis-sponsored study.

Reasons To Buy This Report

The Gastric Neuroendocrine Tumors Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for gastric neuroendocrine tumors. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within gastric neuroendocrine tumors pipeline insights.

Key Questions Answered in the Gastric Neuroendocrine Tumors – Pipeline Assessment Report

• What is the current landscape of gastric neuroendocrine tumors pipeline drugs?
• How many companies are developing gastric neuroendocrine tumors drugs?
• How many phase III and phase IV drugs are currently present in gastric neuroendocrine tumors pipeline drugs?
• Which companies/institutions are leading the gastric neuroendocrine tumors drug development?
• What is the efficacy and safety profile of gastric neuroendocrine tumors pipeline drugs?
• What are the opportunities and challenges present in the gastric neuroendocrine tumors drug pipeline landscape?
• Which company is conducting major trials for gastric neuroendocrine tumors drugs?
• What geographies are covered in gastric neuroendocrine tumors clinical trials?
• What are emerging trends in gastric neuroendocrine tumors clinical trials?

Related Reports

Neuroendocrine Tumours Treatment Market

Neuroendocrine Carcinoma Market

Global Cancer Tumor Profiling Market